首页> 美国卫生研究院文献>Oncotarget >The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol dihydrotestosterone microRNAs and genes related to breast cancer
【2h】

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol dihydrotestosterone microRNAs and genes related to breast cancer

机译:雌二醇二氢睾丸激素microRNA和与乳腺癌有关的基因对乳腺癌细胞系中羟类固醇17β-脱氢酶1型和2型基因表达的调节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim. To investigate the influence of estrogen, androgen, microRNAs, and genes implicated in breast cancer on the expression of HSD17B1 and HSD17B2. Materials. Breast cancer cell lines ZR-75-1, MCF7, T47D, SK-BR-3, and the immortalized epithelial cell line MCF10A were used. Cells were treated either with estradiol or dihydrotestosterone for 6, 24, 48 hours, or 7 days or treated with miRNAs or siRNAs predicted to influence HSD17B expression Results and discussion. Estradiol treatment decreased HSD17B1 expression and had a time-dependent effect on HSD17B2 expression. This effect was lost in estrogen receptor-α down-regulated or negative cell lines. Dihydrotestosterone treatment increased HSD17B2 expression, with limited effect on HSD17B1 expression. No effect was seen in cells without AR or in combination with the AR inhibitor hydroxyflutamide. The miRNA-17 up-regulated HSD17B1, while miRNA-210 and miRNA-7-5p had up- and down-regulatory effect and miRNA-1304-3p reduced HSD17B1 expression. The miRNA-204-5p, 498, 205-3p and 579-3p reduced HSD17B2 expression. Downregulation of CX3CL1, EPHB6, and TP63 increased HSD17B1 and HSD17B2 expression, while GREB1 downregulation suppressed HSD17B1 and promoted HSD17B2 expression. Conclusion. We show that HSD17B1 and HSD17B2 are controlled by estradiol, dihydrotestosterone, and miRNAs, as well as modulated by several breast cancer-related genes, which could have future clinical applications.
机译:目标。研究雌激素,雄激素,microRNA和基因与乳腺癌有关对HSD17B1和HSD17B2表达的影响。材料。使用了乳腺癌细胞系ZR-75-1,MCF7,T47D,SK-BR-3和永生化的上皮细胞系MCF10A。将细胞用雌二醇或二氢睾丸酮处理6、24、48小时或7天,或用预测会影响HSD17B表达的miRNA或siRNA处理。结果和讨论。雌二醇处理降低了HSD17B1的表达,并对HSD17B2的表达具有时间依赖性。这种作用在雌激素受体-α下调或阴性细胞系中消失。双氢睾酮治疗可增加HSD17B2表达,但对HSD17B1表达的作用有限。在没有AR或与AR抑制剂羟基氟他胺联用的细胞中未见效果。 miRNA-17上调HSD17B1,而miRNA-210和miRNA-7-5p则有上调和下调作用,而miRNA-1304-3p则降低HSD17B1的表达。 miRNA-204-5p,498、205-3p和579-3p降低了HSD17B2的表达。 CX3CL1,EPHB6和TP63的下调增加了HSD17B1和HSD17B2的表达,而GREB1的下调抑制了 HSD17B1 并促进了 HSD17B2 表达。结论。我们显示, HSD17B1 HSD17B2 受雌二醇,二氢睾丸激素和miRNA的控制,并受几种与乳腺癌相关的基因的调控,这可能具有未来的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号